Skip to main content

Table 3 Univariate and multivariate Cox regression analysis for OS in 158 patients

From: Arterial enhancement fraction in evaluating the therapeutic effect and survival for hepatocellular carcinoma patients treated with DEB-TACE

Variables

Univariate

Multivariate

HR (95% CI)

p

HR (95% CI)

p

Age > 55 (years)

0.70 (0.46, 1.06)

0.096

0.95 (0.60, 1.49)

0.818

Male

0.92 (0.52, 1.63)

0.778

1.49 (0.81, 2.76)

0.203

Child–Pugh B class

1.10 (0.65, 1.84)

0.722

1.02 (0.56, 1.83)

0.959

AFP > 400 (ng/ml)

2.24 (1.48, 3.40)

<  0.001

1.45 (0.92, 2.28)

0.110

Multifocal disease

2.45 (1.59, 3.77)

<  0.001

1.40 (0.87, 2.25)

0.171

Lesion diameter (cm)

1.20 (1.14, 1.26)

<  0.001

1.17 (1.10, 1.25)

<  0.001

Macrovascular invasion

3.90 (2.54, 5.99)

<  0.001

3.45 (2.09, 5.70)

<  0.001

Repeated treatment courses

0.79 (0.60, 1.05)

0.099

0.52 (0.37, 0.72)

<  0.001

AEFpre > 57.95%

1.66 (1.09, 2.55)

0.019

2.29 (1.42, 3.68)

0.001

  1. OS Overall survival, HR Hazard ratio, AFP α-fetoprotein, AEF Arterial enhancement fraction